Microsoft word - m miller - bio summary.doc
Head, Division of Infectious Diseases Chief, Department of Microbiology SMBD-Jewish General Hospital, Montreal, Quebec, Canada
Dr. Mark Miller graduated from medical school at McGill University in 1982 and
then did specialty training in Montreal in the fields of Internal Medicine, Infectious Diseases and in Medical Microbiology, for which he received Royal College and Quebec certification in 1988. He then pursued a Master’s degree in Epidemiology and Biostatistics at McGill, which he received in 1990. His Master’s research focused on the genetic factors which determine resistance to tuberculosis among Canadian aboriginal people in Alberta.
He was a staff microbiologist and infectious disease specialist at the Montreal
General Hospital for 5 years, and then moved to the SMBD-Jewish General Hospital in 1993, where he became the Chair of Infection Prevention and Control, the Chief of Microbiology, and the Head of the Division of Infectious Diseases. Subsequently, the bulk of his research has been in the epidemiology, prevention, and treatment of nosocomial (i.e. hospital-acquired) infections. He has described the rapid emergence of mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) during use of this antibiotic in outbreak control, chaired the cross-Canada group studying the morbidity, health effects, and death rate from hospital-acquired C. difficile-associated diarrhea (CDAD), and headed the Canadian team which surveyed the reuse of single-use medical devices. He is currently concentrating on 4 aspects of CDAD research: i) a follow-up Canadian study of CDAD which will include additional lab-based studies of the organism from affected hospitals, ii) a large CDAD prevention trial using Lactobacillus probiotics, iii) the use of laser-induced emissions for the ultra-rapid diagnosis of CDAD from stool samples, and iv) a review of the utility of IVIG in the therapy of severe CDAD. He also participates in several pharmaceutical-sponsored multi-site clinical trials for the therapy of CDAD.
He was a member of the provincial committee, created by the Quebec Hospital
Association and the Association of Microbiologists of Quebec, which established guidelines for the reuse of single-use medical devices (2004) In addition, he was also a member of the committee formed by the Order of Physicians of Quebec which wrote the guidelines applicable to physicians infected with blood-borne diseases (2004).
Since 1996, he has been the chairman of the Infection Control Working Group of
the McGill University Teaching Hospital Council (MUTHC), in an effort to harmonize infection prevention and control practices in the Faculty of Medicine and in all McGill-affiliated health institutions.
He has co-authored 75 peer-reviewed articles and 83 abstract presentations and
continues to publish studies mainly in the field of nosocomial infections. He has also written regular columns about infectious diseases in the Montreal Gazette, and writes humourous articles for the medical magazine “Stitches” on a regular basis.
He is the past-president of the Association of Medical Microbiology and Infectious
Disease of Canada (AMMI-Canada), the professional society of over 500 Canadian physicians involved in the prevention, diagnosis, treatment, and research in the vast field of Infectious Diseases.
Dr. Miller has two children - a 24 year-old daughter and a 20 year-old son- and
Middle East Section 2011 Annual Report Farha Ghannam (email@example.com) I. Section Officers Position: President Name: Farha Ghannam Email: firstname.lastname@example.org Position: Past-president Name: Gregory Starrett Email: email@example.com Position: Treasurer Name: Fida Adely Email: firstname.lastname@example.org Position: Secretary Name: Kamran Ali Email: asda
Multi-dose vial management The Centers for Disease Control and Prevention administration rather than multi-dose vials due to the (CDC) and the World Health Organization (WHO) risk of cross contamination and the potential to have developed recommendations and guidelines administer too high of a dose to patients.6 regarding best practices for infection control. These recommen